RxDoctor Payments Data

Jeffrey Najor, MD

Internal Medicine · Southfield, MINPI 1124381827

Payments from drug & device makers

$20,018in general payments, 2019–2025

Across 922 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$2K
  • Novo Nordisk$1K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Lundbeck LLC$1K
  • plus $11K from 48 others

What the payments were for

  • Food & beverage$20,012100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)164$2,714
Pfizer79$1,675
Novo Nordisk79$1,226
Johnson & Johnson13$1,064
AstraZeneca49$1,060
Lundbeck LLC53$1,004
Lilly USA, LLC33$827
Otsuka America Pharmaceutical, Inc.30$814
Gilead36$713
Axsome Therapeutics, Inc.32$705
Shield Therapeutics Inc41$678
Alkermes, Inc.36$654
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)28$630
Bayer21$605
Takeda Pharmaceuticals U.S.A., Inc.31$578
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)6$403
Merck16$402
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$353
GSK16$316
Vanda Pharmaceuticals Inc.5$267
Exact Sciences12$266
Amgen(2 entities)8$245
Biohaven Pharmaceuticals, Inc.13$236
Biohaven Pharmaceutical Holding Company Ltd.9$216
Tris Pharma Inc7$213
Astellas Pharma US Inc11$213
Teva Pharmaceuticals USA, Inc.4$191
Supernus Pharmaceuticals, Inc.10$173
Sunovion Pharmaceuticals Inc.14$169
E.r. Squibb & Sons, L.L.C.4$166
Abiomed2$140
Cardiovascular Systems Inc.2$131
Corcept Therapeutics1$125
Nevro Corp.1$124
Dexcom, Inc.1$100
Boehringer Ingelheim5$87
Harmony Biosciences LLC2$61
Novartis3$48
Neurocrine Biosciences, Inc.2$43
Theratechnologies Inc.2$41
Sumitomo Pharma America, Inc.2$41
Verona Pharma, Inc.2$39
Xeris Pharmaceuticals, Inc.2$37
Idorsia Pharmaceuticals US Inc2$35
Almatica Pharma LLC2$27
Mimedx Group, Inc.1$27
Nestle Healthcare Nutrition Inc.1$22
Esperion Therapeutics, Inc.1$20
Actelion Pharmaceuticals US, Inc.1$20
TMS Neurohealth Centers Inc.1$16
Medtronic1$16
Sanofi-aventis U.S. LLC1$15
Arbor Pharmaceuticals, Inc.1$15
Sun Pharmaceutical Industries Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,018 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$339,849
Medicare patients
110
Services billed
1,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol344$229,848
MounjaroTirzepatide197$220,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter249$189,139
VraylarCariprazine Hcl61$88,962
EliquisApixaban129$84,130
TrulicityDulaglutide67$71,649
JardianceEmpagliflozin86$63,567
LinzessLinaclotide107$58,825
RexultiBrexpiprazole38$57,789
TrintellixVortioxetine Hydrobromide82$49,746
RybelsusSemaglutide33$48,886
MyrbetriqMirabegron68$31,491
AuvelityDextromethorphan Hbr/Bupropion25$25,962
EntrestoSacubitril/Valsartan21$18,001
OzempicSemaglutide16$15,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Zyprexa$827$297,241275 claims
AstraZenecaFarxiga$1,060$229,848344 claims
GSKTrelegy Ellipta$316$189,139249 claims
AbbVieVraylar, Linzess$2,714$147,787168 claims
PfizerEliquis, Nurtec Odt$1,675$97,553143 claims
Novo NordiskRybelsus, Ozempic$1,226$64,36749 claims
Boehringer IngelheimJardiance$87$63,56786 claims
Otsuka America Pharmaceutical, Inc.Rexulti$814$57,78938 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$578$49,74682 claims
Astellas Pharma US IncMyrbetriq, Veozah$213$43,08089 claims
Axsome Therapeutics, Inc.Auvelity$705$25,96225 claims
MerckJanuvia, Verquvo$402$19,37629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →